



Medicines & Healthcare products
Regulatory Agency



MHRA

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Ms Ruth Nicholson
IMPERIAL COLLEGE LONDON
5TH FLOOR, SHERFIELD BUILDING,
SOUTH KENSINGTON CAMPUS
LONDON
SW7 2BB
UNITED KINGDOM

01/07/2025

Dear Ms Ruth Nicholson

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference:	CTA 19174/0458/001-0001
IRAS ID:	1008743
Product:	Simvastatin, Baricitnib
Protocol number:	175151

NOTICE OF ACCEPTANCE OF AMENDED REQUEST

I am writing to inform you that the Licensing Authority, having reviewed your application in collaboration with the Research Ethics Committee, accepts your amended request for a clinical trial authorisation (CTA), with effective received date of 19/03/2025.

COMBINED REVIEW MEDICAL

PHARMACEUTICAL

The authorisation is effective from the date of this letter although your trial may be suspended or terminated at any time by the Licensing Authority in accordance with regulation 31. You must notify the Licensing Authority within 90 days of the trial ending.

You are reminded that a favourable opinion from the Ethics Committee is also required before this trial can proceed, changes made as part of your amended request may need to be notified to the Ethics Committee. If not already provided, please follow the guidance on our website on informing us of the registration status of your trial (where applicable).

You are reminded that from 1 January 2022 you will need to comply with the requirements specified in the following guidance, where applicable:

Import of IMPs from listed countries to GB:

<https://www.gov.uk/government/publications/importing-investigational-medicinal-products-into-great-britain-from-approved-countries>

Supply of IMPs to Northern Ireland:

<https://www.gov.uk/guidance/supplying-investigational-medicinal-products-to-northern-ireland>

Substantial amendments to clinical trials:

<https://www.gov.uk/guidance/guidance-on-substantial-amendments-to-a-clinical-trial>

Any required substantial amendment to your Clinical Trial Authorisation should be submitted and approved as soon as possible and before 1 January 2022.



Yours sincerely,

Clinical Trials Unit
MHRA